Broken String Biosciences ("Broken String"), a leader in advancing gene editing safety, today opened its Catalyst Early ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

The National Institute for Health and Care Excellence (NICE) has approved a one-off gene editing therapy to treat severe sickle cell disease (SCD) in people 12 years and over. In final draft guidance1 ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

This new on-demand offering enables gene editing therapy developers to assess on- and off-target effects in days, as opposed to months. The offering can be integrated into early therapeutics ...